At less than 8 times trailing earnings, Western Union looks like a bargain. Royalty Pharma could grow its specialty financing ...

专注于制药的Royalty Pharma plc (NASDAQ:RPRX)宣布,在美国食品和药物管理局(FDA)批准一种新的精神分裂症治疗方法后,公司达成了一个重要里程碑。周四,Bristol Myers Squibb (BMS)获得FDA批准,可以将KarXT (xanomeline-trospium)以Cobenfy的商品名上市,用于治疗成年人的精神分裂症。 这项批准触发了Royalty P ...

智通财经APP获悉，美国食品和药物管理局(FDA)周四批准了由美国医药巨头百时美施贵宝公司(BMY.US)开发的Cobenfy(xanomeline以及trospium ...

UBS has recently reduced Royalty Pharma plc (RPRX) stock to Neutral rating, as announced on June 3, 2024, according to Finviz. Earlier, on June 14, 2022, UBS had resumed the stock to Buy, setting a ...

随着生物技术公司的兴起和大型制药企业的持续发展，CEO们的薪酬包也水涨船高。 Endpoints News通过对数百家企业的CEO薪酬进行统计，评选出了2023年薪酬最高的20位生物制药公司CEO。这些薪酬不仅包括基本工资，还涵盖了各种期权奖励等。

美国食品和药物管理局 (FDA)周四批准了由美国医药巨头百时美 施贵宝 公司 (BMY.US)开发的Cobenfy (xanomeline以及trospium chloride)，作为治疗精神分裂症成人患者的最新疗法。受益于这一利好消息，周五百时美施贵宝股价在美股盘前交易中一度大涨约 6%，今年以来该公司股价可谓长期低迷。该公司宣布计划在10月底推出 Cobenfy，每月定价 1850 ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

This approval triggers 2 milestone payments totaling $29 million, as per agreements with Royalty Pharma and PureTech's founded entity, Karuna Therapeutics, which was acquired by Bristol Myers Squibb ...

On Tuesday, Royalty Pharma plc (RPRX) stock saw a modest uptick, ending the day at $27.71 which represents no change from the prior close of $27.71. The stock opened at $27.71 and touched a low of $27 ...

Biotech companies could gain the financial flexibility to accelerate their innovations with the Fed’s recent rate cut. To ...

Invented KarXT Receives U.S. Food and Drug Administration Approval for the Treatment of Schizophrenia in Adults ...

随着Ascendis Pharma (NASDAQ:ASND)继续在其TransCon CNP治疗方面取得进展，考虑公司的财务健康状况和市场表现是有价值的。目前市值为68.4亿美元的Ascendis正以较高的收入估值倍数交易，这反映了市场对未来增长的期望，特别是考虑到其最近3期试验的成功。尽管在过去十二个月内未盈利，但公司在同期内收入增长显著，达166.54%。这种增长轨迹可能是Ascendis ...